期刊文献+

来氟米特治疗大鼠系膜增生性肾炎对炎性因子改善的观察 被引量:1

Effect of leflunomide on inflammatory response to rat mesangial proliferative glomerulonephritis
暂未订购
导出
摘要 目的探讨来氟米特对系膜增生性肾小球肾炎的治疗作用及对炎性因子的改善情况。方法 36只SD雄性大鼠随机分为3组:正常对照组(n=12);模型组(n=12);治疗组(n=12)。各组大鼠均于实验4、8、12周末检测24 h尿蛋白定量、血清胱抑素C、血肌酐水平,HE染色光镜下观察肾组织系膜增生程度;免疫组化二步法检测TLR4、NF-κB、细胞因子IL-6、TNF-α的表达情况。结果对照组大鼠24 h尿蛋白定量、血清胱抑素C、血肌酐水平、肾组织系膜增生程度、TLR4、NF-κB及细胞因子IL-6、TNF-α的水平均低于模型组、治疗组(P<0.05);与模型组相比,治疗组上述指标明显减低(P<0.05)。结论来氟米特可通过抑制TLR4、NF-κB及细胞因子IL-6、TNF-a的水平对系膜增生性肾小球肾炎发挥治疗作用。 Objective To investigate the therapeutic effect of leflunomide on mesangial proliferative glomerulonephritis and the role of TLR4 signaling pathway in rat mesangial proliferative glomerulonephritis. Methods A total of 36 normal male Sprague-Dawley rats were randomly divided into 3 groups: normal control group (n=12), model group (n=12) and treatment group (n=12). Rats in each group were tested 24-hour urinary protein excretion, serum cystatin C and serum creatinine levels in the end of 4,8 and 12 weeks to observe the mesangial proliferative extent of renal tissue under light microscope after HE staining . Two-step immunohistochemical methods were used to detect the changes in the expression of TLR4, NF-κB, cytokines IL-6 and TNF-α. Results Levels of 24-hour urinary protein excretion, serum cystatin C, serum creatinine, mesangial proliferation of renal tissue, TLR4, NF-κB cytokine IL-6 and TNF-α in model group and treatment group were higher than those in normal control group (P〈0.05),levels in treatment group were significantly lower than those in model group (P〈0.05). Conclusions Leflunomide has a therapeutic effect on mesangial proliferative glomerulonephritis by inhibiting TLR4 signaling pathway and NF-κB cytokine IL-6 and TNF-α.
出处 《武警医学》 CAS 2013年第10期853-856,859,共5页 Medical Journal of the Chinese People's Armed Police Force
关键词 来氟米特 系膜增生性肾小球肾炎 炎性因子 leflunomide mesangial proliferative glomerulonephritis inflammatory factors
  • 相关文献

参考文献10

  • 1Tam I, S, Li E K, Wong CK, et d. Safety and effh'acv of leflunonlhle in the lreatmenl of lupus nephritis refrac- tory or intoleranl Io lraditiona] inmnmosuppressiw" thera- py: an open label triaIIJl]. Ann Rheum I)is,2006,65 (3) :417 -418.
  • 2Liu X W, Li D M, Xu G S, el tl. (omparison of lhe therapeutic eflcts of letlunomide and mycophenolah mofeti[ in l|le h'eatment of immunogh)butin A nel)hropa- Ihy manifesting with nephmtic syndrome[ J i. In! J (21in Pharmaeol Ther,2010,48 ( 8 ) :509 - 513.
  • 3丛敏,江蓓,胡昭,李伟,苗华,付玉芹,李延国.来氟米特治疗原发性难治性肾病综合征的多中心临床观察[J].山东大学学报(医学版),2007,45(3):295-298. 被引量:13
  • 4lan C, Davis, Eduardo R,et al. I,eflunonlide Pllevlnls Alveolar Fluid Clearance Inhibilion by Respiratory Syn- cytial Virus [ J ]. Amrican Jurnal of Respirahry md Critical Care Medicine, 2006,173:673 - 682.
  • 5孙剑,张浩,刘纪实,徐果,易斌.来氟米特与霉酚酸酯治疗表现为肾病综合征的过敏紫癜性肾炎的疗效比较[J].中国中西医结合肾病杂志,2008,9(8):691-693. 被引量:15
  • 6Mecormiek D, Hall P. The Complexities of prolifemting cell nuclear antigen [ J ]. Histopathology, 1992,21,591 - 594.
  • 7Huiling W, Gang C, Kate R, et al. TLR4 activation mediates kidney ischemia/reperfusion injury[J]. J Clin Invest, 2007, 117(10):2847 - 2859.
  • 8Vabulas R M, Braedel S, Hill N, et al. The endoplas- mic reticulum - resident heat shock protein Gp96 acti- vates dendritic cells via the Toll - like receptor 2/4pathwayJ. J Biol Chem ,2002 ,277 (23) :20847 20853.
  • 9Verma A, Prasad KN, Gupta RK, et al. Toll like receptor 4 polymorphism and its associatio n with symptomatic neurocysticercosis[J]. J Infect Dis,2010,202(8) :1219 - 1225.
  • 10I Gonz61ez- Mvarol, A M Ortizl, C Dominguez - Jim6nezl, et al. Inhibition of tumour necrosis factor and IL- 17 production by leflunomide involves the JAK/ STAT pathway [ J ]. Ann Rheum Dis, 2009,68 ( 10 ) : 1644 - 1650.

二级参考文献12

  • 1崔太根,侯凡凡,倪兆慧,陈香美,张凤山,朱彤莹,赵学智,鲍春德,赵明辉,王国保,钱家麒,蔡广研,李英楠,陆福明,梅长林,邹万忠,王海燕.来氟米特联合糖皮质激素治疗增殖型狼疮性肾炎的多中心对照临床试验研究[J].中华内科杂志,2005,44(9):672-676. 被引量:103
  • 2林炯程,胡伟新,唐政,陈惠萍,章海涛,杨光,张炯,刘志红,黎磊石.霉酚酸酯与环磷酰胺治疗重症过敏紫癜性肾炎的疗效比较[J].肾脏病与透析肾移植杂志,2005,14(6):508-513. 被引量:25
  • 3王海燕 郑法雷 等.原发性肾小球疾病分型与治疗及诊断标准专题座谈会纪要[J].中华内科杂志,1993,2:131-134.
  • 4Wozel G,Feiffer C.Leflunomide-a new drug for pharmacological immunomodulation[J].Hautarzt,2002,53(5):309-315.
  • 5Maddisom P,Kiely P,Kirkham B,et al.Leflunomide in rheumatoid arthritis:recommendations through a process of consensus[J].Rheumatology (Oxford),2005,44(3):280-286.
  • 6Xiao F,Chong A,Shen J,et al.Pharmacologically induced regession of chronic transplant rejection[J].Transplantation,1995,60(10):1 065-1 072.
  • 7Tam LS,Li EK,Wong CK,et al.Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy:an open label trial[J].Ann Rheum Dis,2006,65(3):417-418.
  • 8Lou T,Wang C,Chen Z,et al.Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy[J].Nephrology,2006,11(2):113-116.
  • 9Gulati S,Pokhariyal S,Sharma RK,et al.Pulse cyclophosphamide therapy in frequently relapsing nephritic syndrome[J].Nephrol Dial Trans Plant,2001,16(10):2 013-2 027.
  • 10胡伟新,唐政,姚小丹,沈克勤,黎磊石.间断环磷酰胺冲击治疗难治性紫癜性肾炎的疗效观察[J].肾脏病与透析肾移植杂志,1997,6(1):12-16. 被引量:15

共引文献25

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部